Cancer Stem Cells and Advanced Novel Technologies in Oncotherapy

Author:

Sakthivel Shalini1,Srivastava Manjita2,Barman Muneesh Kumar3,Ravichandiran Nerethika1,Martins Salonee2,Singh Meenakshi4,Chand Kailash5,Sonkar Subash C.6ORCID,Bhukya Prudhvilal7ORCID

Affiliation:

1. Department of Bio-Medical Science, Bharathidasan University, India

2. National Institute of Virology (ICMR), India

3. Laboratory for HIV Research, National Centre for Cell Sciences, Pune, India

4. Transplant Immunology and Immunogenetics Lab (HLA), ACTREC, Tata Memorial Centre, India

5. National Centre for Cell Sciences, Pune, India

6. Multidisciplinary Research Unit, Department of Biochemistry, New Delhi, India

7. National Institute of Virology (ICMR), Pune, India

Abstract

Self-renewal is the most important property of stem cells. Parallel to this, cancer stem cells (CSCs) have an indefinite proliferative ability that drives tumorigenesis. The conventional treatment of cancer includes chemotherapy, radiotherapy, and surgery, which decreases the tumour size. Contrary, targeted therapy against CSCs initially does not shrink the tumour but ultimately causes tumour degeneration. Nanobiotechnology, RNA interference, microRNA are emerging fields with a vital role in targeted therapy against CSCs. The non-protein encoding microRNAs has a major role in cancer treatment since they regulate gene expression during post-transcription. RNAi technology can silence the gene of interest with potency and specificity inhibiting tumour growth. In nanoparticles-based RNA interference, nanocarriers protect RNAi molecules from immune recognition and enzymatic degradation. The cancer cell gene expression profiling using next-generation sequencing helps in understanding the underlying cancer cell mechanisms. The current chapter deals with novel concepts in the treatment of cancer.

Publisher

IGI Global

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3